Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  lapatinib ditosylate
Find trials that include:  Any drugs shown
Results 1-20 of 20 for your search:
Start Over
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
Lapatinib Ditosylate and Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-437, NCI-2013-00670, NCT00881621
Control or Extended Lapatinib Ditosylate and Trastuzumab With or Without Goserelin Acetate or Letrozole in Treating Patients With HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TBCRC 023, NCI-2012-01766, H-25846, NCT00999804
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 15309, NCI-2009-01492, NCT01044433
Lapatinib Ditosylate and Trastuzumab in Treating Older Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 10112, NCI-2011-00116, 105241, 115357, NCT01273610
Targeted Enzyme Inhibitor Therapy in Treating Patients with Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, P8639_A15PAMDREVW01, 8639, NCT01306045
Lapatinib Ditosylate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LAP115352, NCI-2012-00779, NCT01591577
Whole-Brain Radiation Therapy with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1119, NCI-2012-01977, CDR0000735353, NCT01622868
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RF-3501, NCI-2014-01403, LAP116153, NCT01711658
Lapatinib Ditosylate and Radiation Therapy in Treating Patients with Locally Advanced or Locally Recurrent Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BRS0027, NCI-2013-01065, 26601, NCT01868503
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients with HER2-Positive Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1B-12-10, NCI-2013-01086, HS-13-00084, NCT01873833
Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 05B5, NCI-2011-00325, NU-1838-001, NCT00316875
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients with Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated with Trastuzumab Only
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-0842, NCI-2011-03222, CDR0000710891, 8871, MDA-2010-0842, NCT01434303
Lapatinib Ditosylate and Bortezomib in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-533, NCI-2013-00659, NCT01497626
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-061, NCI-2013-01748, 9354, NCT01947023
Trastuzumab, Pertuzumab, and Lapatinib Ditosylate in Measuring Kinome Response in Patients with HER2+ Breast Cancer Undergoing Surgery
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: LCCC 1214, NCI-2014-01407, 13-1826, NCI-2014-00972, NCT01875666
Lapatinib Tosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1302, NCI-2014-00634, NCT02101905
Veliparib and Lapatinib Ditosylate in Treating Patients with Triple Negative Metastatic Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1372, NCI-2015-00265, F131219003, NCI-2014-02253, NCT02158507
Start Over